RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2008; 133(23): 1259-1264
DOI: 10.1055/s-2008-1077250
DOI: 10.1055/s-2008-1077250
Übersicht | Review article
Epidemiologie
© Georg Thieme Verlag KG Stuttgart · New York
Bedeutung des Neuraminidase-Inhibitors Oseltamivir in der Therapie der saisonalen Influenza
Management of seasonal influenza with the neuraminidase inhibitor oseltamivirWeitere Informationen
Publikationsverlauf
eingereicht: 17.12.2007
akzeptiert: 31.3.2008
Publikationsdatum:
29. Mai 2008 (online)
Schlüsselwörter
Influenza - Epidemie - Neuraminidasehemmer - Oseltamivir - Sekundärkomplikationen
Key words
influenza - epidemic - neuraminidase inhibitors - oseltamivir - secondary complications
Literatur
- 1 Aoki F Y, MacLeod M D, Paggiaro P. et al . Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003; 51 123-129
- 2 Arbeitsgemeinschaft Influenza. Abschlussberichte der Saisons 2002 - 2007, http://influenza.rki.de/index.html?c = saisonbericht.
- 3 Barr C E, Schulman K, Iacuzio D. et al . Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin. 2007; 23 (3) 523-531
- 4 Bhat N, Wright J G, Broder K R. et al . Influenza-associated deaths among children in the United States, 2003 - 2004. N Engl J Med. 2005; 353 2559-2567
- 5 Falsey A R, Murata Y, Wlash E E. et al . Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med. 2007; 167 (4) 354-360
- 6 Goodwin K, Viboud C, Simonsen S. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine. 2006; 24 1159-1169
- 7 Hayden F G, Atmar R L, Schilling M. et al . Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999; 341 (18) 1336-1343
- 8 Hayden F G, Treanor J J, Fritz R S. et al . Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999; 282 1240-1246
- 9 Hayden F G, Robson R, Jennings L. et al . Efficacy of oral oseltamivir in experimental human influenza B virus infection (abstract). Clin Infect Dis. 1999; 282 1240-1246
- 10 Holm M V, Blank P R, Szucs T. Trends in influenza vaccination coverage rates in Germany over five seasons from 2001 to 2006. BMC Infect Dis. 2007; 7 144
- 11 Jefferson T. Influenza vaccination: policy versus evidence. BMJ. 2006; 333 (7574) 912-915
- 12 Jefferson T O, Rivetti D, DiPietrantonj C. et al . Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007; (2) , CD001269
- 13 Jefferson T O, Rivetti D, Rivetti A. et al . Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005; 366 (9492) 1165-74 , Review. Erratum in: Lancet 2006 Mar 25; 367(9515): 986
- 14 Kaiser L, Wat C, Mills T. et al . Impact of oseltamivir treatment on influenza-related respiratory tract complications and hospitalisations. Arch Intern Med. 2002; 163 1667-1672
- 15 Leitmeyer K, Buchholz U, Kramer M. et al . Influenza vaccination in German health care workers: effects and findings after two rounds of a nationwide awareness campaign. Vaccine. 2006; 24 70003-70008
- 16 Lin J T, Yu X Z, Cui D J. et al . A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin. 2006; 22 (1) 75-82
- 17 Machado C M, Boas L S, Mendes A V. et al . Use of Oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant. 2004; 34 (2) 111-114
- 18 McGeer A, Green K, Plevneshi A. et al, for the Toronto Invasive Bacterial Diseases Network . Antiviral therapy and outcomes of influenza requiring Hospitalization in Ontario, Canada. Clin Infect Dis. 2007; 45 (12) 1568-1575
- 19 Meier C R, Napalkow P N, Wegmüller Y. et al . Population-based study on incidence, risk factors, clinical complications and drug utilisation associtaed with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000; 19 834-842
- 20 Monto A S, McKimm-Breschkin J L, Macken C. et al . Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006; 50 (7) 2395-2402
- 21 Nichols W G, Guthrie K A, Corey L. et al . Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004; 39 (9) 1300-1306
- 22 Nicholson K G, Aoki F Y, Vrooman P S. et al . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000; 355 1845-1850
- 23 Nordstrom B L, Sung I, Suter P. et al . Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin. 2005; 21 761-768
- 24 Patriarca P A, Weber J A, Meissner M K. et al . Use of influenza vaccine in nursing homes. J Am Geriatr Soc. 1985; 33 (7) 463-466
- 25 Patriarca P A, Weber J A, Parker R A. et al . Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol. 1986; 124 (1) 114-119
- 26 Peters Jr P H, Gravenstein S, Norwood P. et al . Long-term use of oseltamivir in the prophylaxis of influenza in household contacts. A randomized controlled trial. Journal of the American Geriatric Society. 2001; 49 1025-1031
- 27 Shugarman L R, Hales C, Setodji C M. et al . The influence of staff and resident immunization rates on influenza-like illness outbreaks in nursing homes. J Am Med Dir Assoc. 2006; 7 (9) 562-567
- 28 Simonsen L, Taylor R J, Viboud C. et al . Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007; 7 658-666
- 29 Stevenson C G, McArthur M A, Naus M. et al . Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: how are we doing?. CMAJ. 2001; 164 (10) 1413-1419
- 30 Thompson W W, Shay D K, Weintraub E. et al . Influenza-associated hospitalizations in the United States. JAMA. 2004; 292 (11) 1333-1340
- 31 Treanor J J, Hayden F G, Vrooman P S. et al . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000; 283 (8) 1016-1024
- 32 Uphoff H, Groniewicz I, Soriano M. et al . A surveillance system for the real-time reporting of influenza activity. Dis Manage Health Outcomes. 2004; 12 (3) 197-206
- 33 Ward P, Small I, Smith J. et al . Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005; 55 Suppl 1 i5-i21
- 34 Welliver R, Monto A S, Carewicz O. et al . Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001; 285 (6) 748-754
- 35 Whitley R J, Hayden F G, Reisinger K S. et al . Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20 (2) 127-33 , Erratum in: Pediatr Infect Dis J 2001; 20(4): 421
Prof. Dr. Bernhard R. Ruf
2. Klinik für Innere Medizin, Klinikum St. Georg
Delitzscher Str. 141
04129 Leipzig
Telefon: 0341/909-2601
Fax: 0341/909-2630
eMail: ruf@sanktgeorg.de